Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
In: Computational and Structural Biotechnology Journal, Jg. 18 (2020), S. 3402-3414
Online
unknown
Zugriff:
Graphical abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is a novel beta coronavirus. SARS-CoV-2 uses spike glycoprotein to interact with host angiotensin-converting enzyme 2 (ACE2) and ensure cell recognition. High infectivity of SARS-CoV-2 raises questions on spike-ACE2 binding affinity and its neutralization by anti-SARS-CoV monoclonal antibodies (mAbs). Here, we observed Val-to-Lys417 mutation in the receptor-binding domains (RBD) of SARS-CoV-2, which established a Lys-Asp electrostatic interaction enhancing its ACE2-binding. Pro-to-Ala475 substitution and Gly482 insertion in the AGSTPCNGV-loop of RBD possibly hinders neutralization of SARS-CoV-2 by anti-SARS-CoV mAbs. In addition, we identified unique and structurally conserved conformational-epitopes on RBDs, which can be potential therapeutic targets. Collectively, we provide new insights into the mechanisms underlying the high infectivity of SARS-CoV-2 and development of effective neutralizing agents.
Titel: |
Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
|
---|---|
Autor/in / Beteiligte Person: | Choi, Sangdun ; Shah, Masaud ; Hyun Goo Woo ; Ahmad, Bilal |
Link: | |
Zeitschrift: | Computational and Structural Biotechnology Journal, Jg. 18 (2020), S. 3402-3414 |
Veröffentlichung: | Elsevier, 2020 |
Medientyp: | unknown |
ISSN: | 2001-0370 (print) |
Schlagwort: |
|
Sonstiges: |
|